MedTrace Logo

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

NCT03837327 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1025

Last updated 2024-04-23

No results posted yet for this study

Summary

Venn Biosciences Corporation ("InterVenn") has developed a liquid biopsy that is capable of distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test. The underlying technology combines mass spectrometry and artificial intelligence/machine learning to analyze tumor-associated changes in circulating glycoproteins.

The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, in order to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically confirmed malignancy status of the mass.

Conditions

Sponsors & Collaborators

  • Venn Biosciences Corporation

    lead INDUSTRY

Principal Investigators

  • Daniel Hommes, MD · InterVenn Biosciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2024-01-22
Completion
2024-01-22

Countries

  • United States
  • Australia
  • Malaysia
  • Philippines

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03837327 on ClinicalTrials.gov